Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection

Expert Review of Anticancer Therapy

Volumn 7, Issue 6, 2007, Pages 847-862

  Breda, Alberto ^a   Konijeti, Ramdev ^a   Lam, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinoma; Imaging; Kidney; Nephrectomy; Recurrence; Surveillance

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 2; PLACEBO; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANAMNESIS; ANXIETY; BONE METASTASIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; ENZYME INHIBITION; FAMILIAL CANCER; FLU LIKE SYNDROME; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; LABORATORY TEST; LIVER METASTASIS; LUNG EDEMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR BIOLOGY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEPHRECTOMY; OUTCOMES RESEARCH; OVERALL SURVIVAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34347237585     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.6.847     Document Type: Review

References (163)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999).
3. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J. Urol. 167, 57-60 (2002).
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
5. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28, 1165-1177 (1971).
6. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J. Clin. Oncol. 12, 206-212 (1994).
7. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J. Urol. 173, 1853-1862 (2005).
8. Lam JS, Belldegrun AS, Figlin RA. Advances in immune-based therapies of renal cell carcinoma. Expert Rev. Anticancer Ther. 4, 1081-1096 (2004).
9. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J. Natl Cancer Inst. 98, 1331-1334 (2006).
10. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J. Urol. 176, 2397-2400; discussion 2400 (2006).
11. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kemion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J. Urol. 163, 426-430 (2000).
12. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology 56, 58-62 (2000).
13. Sweeney JP, Thornhill JA, Graiger R, McDermott TE, Butler MR. Incidentally detected renal cell carcinoma: pathological features, survival trends and implications for treatment. Br J. Urol. 78, 351-353 (1996).
14. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J. Urol. 170, 2217-2220 (2003).
15. Dechet CB, Sebo T, Farrow G, Blute ML, Engen DE, Zincke H. Prospective analysis of intraoperative frozen needle biopsy of solid renal masses in adults. J. Urol. 162, 1282-1284; discussion 1284-1285 (1999).
16. Snyder ME, Bach A, Kartan MW, Raj GV, Reuter VE, Russo P. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J. Urol. 176, 2391-2395; discussion 2395-2396 (2006).
17. Patard JJ, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Prognostic significance of the mode of detection in renal tumours. Br. J. Urol. Int. 90, 358-363 (2002).
18. Thompson IM, Peek M. Improvement in survival of patients with renal cell carcinoma - the role of the serendipitously detected tumor. J Urol. 140, 487-490 (1988).
19. Bretheau D, Lechevallier E, Eghazarian C, Grisoni V, Coulange C. Prognostic significance of incidental renal cell carcinoma. Eur. Urol. 27, 319-323 (1995).
20. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J. Urol. 175, 425-431 (2006).
21. Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy - natural history, complications, and outcome. Urology 64, 909-913 (2004).
22. Aguirre A, Rinaggio J, Diaz-Ordaz E. Lingual metastasis of renal cell carcinoma. J. Oral Maxillofac. Surg. 54, 344-346 (1996).
23. Green KM, Pantelides E, de Carpentier JP. Tonsillar metastasis from a renal cell carcinoma presenting as a quinsy. J. Laryngol. Otol. 111, 379-380 (1997).
24. Shimizu K, Nagahama M, Kitamura Y et al. Clinicopathological study of clear-cell tumors of the thyroid: an evaluation of 22 cases. Surg. Today 25, 1015-1022 (1995).
25. Murakami S, Yashuda S, Nakamura T et al. A case of renal cell carcinoma with metastasis to the thyroid gland and concomitant early gastric cancer. Surg. Today 23, 153-158 (1993).
26. Parnes RE, Goldberg SH, Sassani JW. Renal cell carcinoma metastatic to the orbit: a clinicopathologic report. Ann. Ophthalmol. 25, 100-102 (1993).
27. Mezer E, Gdal-On M, Miller B. Orbital metastasis of renal cell carcinoma masquerading as Amaurosis fugax. Eur. J. Ophthalmol. 7, 301-304 (1997).
28. Pursner M, Petchprapa C, Haller JO, Orentlicher RJ. Renal carcinoma: bilateral breast metastases in a child. Pediatr. Radiol. 27, 242-243 (1997).
29. Kannan V. Fine-needle aspiration of metastatic renal-cell carcinoma masquerading as primary breast carcinoma. Diagn. Cytopathol. 18, 343-345 (1998).
30. McLauglin SA, Thiel DD, Smith SL, Wehle MJ, Menke DM. Solitary breast mass as initial presentation of clinically silent metastatic renal cell carcinoma. Breast 15, 427-429 (2006).
31. Pagano S, Ruggeri P, Franzoso F, Brusamolino R. Unusual renal cell carcinoma metastasis to the gallbladder. Urology 45, 867-869 (1995).
32. Golbey S, Gerard PS, Frank RG. Metastatic hypernephroma masquerading as acute cholecystitis. Clin. Imaging 15, 293-295 (1991).
33. Fabre JM, Rouanet P, Dagues F, Blanc F, Baumel H, Domergue J. Various features and surgical approach of solitary pancreatic metastasis from renal cell carcinoma. Eur. J. Surg. Oncol. 21, 683-686 (1995).
34. Odori T, Tsuboi Y, Katoh K et al. A solitary hematogenous metastasis to the gastric wall from renal cell carcinoma four years after radical nephrectomy. J. Clin. Gastroenterol. 26, 153-154 (1998).
35. Sadler GJ, Anderson MR, Moss MS, Wilson PG. Metastases from renal cell carcinoma presenting as gastrointestinal bleeding: two case reports and a review of the literature. BMC Gastroenterol. 7, 4 (2007).
36. Bird DJ, Semple JP, Seiler MW. Sarcomatoid renal cell carcinoma metastatic to the heart: report of a case. Ultrasruct. Pathol. 15, 361-366 (1991).
37. Rodriguez A, Kang L, Politis C et al. Delayed metastatic renal carcinoma to prostate. Urology 67, 623 E7-E10 (2006).
38. Fallick ML, Long JP, Ucci A. Metachronous renal cell carcinoma metastases to spermatic cord and penis. Scand. J. Urol. Nephrol. 31, 299-300 (1997).
39. Yamamoto S, Mamiya Y, Noda K, Samejima T, Miki M, Akasaka Y. [A case of metastasis to the seminal vesicle of renal cell carcinoma]. Nippon Hinyokika Gakkai Zasshi 89, 563-566 (1998).
40. Bolkier M, Moskovitz B, Munichor M, Genesin Y, Levin DR. Metastatic renal cell carcinoma to the bladder. Urol. Int. 50, 101-103 (1993).
41. Chinegwundoh FI, Khor T, Leedham PW. Bladder metastasis from renal cell carcinoma. Br. J. Urol. 79, 650-651 (1997).
42. Ovesen H, Gerstenberg T. Vaginal metastasis as the first sign of renal cell carcinoma. A case report and review of the literature. Scand. J. Urol. Nephrol. 24, 237-238 (1990).
43. Varin S, Faure A, Bouc P, Maugars Y, Berthelot JM. Endoneural metastasis of the sciatic nerve disclosing the relapse of a renal carcinoma, four years after its surgical treatment. Joint Bone Spine 73, 760-762 (2006).
44. Merimsky O, Levine T, Chaitchik S. Recurrent solitary metastasis of renal cell carcinoma in skeletal muscles. Tumori 76, 407-409 (1990).
45. Nakagawa H, Mizukami Y, Kimura H, Watanabe Y, Kuwayama N. Metastatic masseter muscle tumour: a report of a case. J. Laryngol. Otol. 110, 172-174 (1996).
46. Linn JF, Fichtner J, Voges G, Schweden F, Storkel S, Hohenfellner R. Solitary contralateral psoas metastasis 14 years after radical nephrectomy for organ confined renal cell carcinoma. J. Urol. 156, 173 (1996).
47. Kim HL, Lam JS, Belldegrun AS. The role of lymphadenectomy in renal cell carcinoma. Curr. Urol. Rep. 5, 25-29 (2004).
48. Bell ET. A classification of renal tumors with observations on the frequency of the various types. J. Urol. 39, 238-243 (1938).
49. Karakiewicz PI, Lewinshtein DJ, Chun FK et al. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. Eur. Urol. 50, 521-528; discussion 529 (2006).
50. Ritchie AW, Layfield LJ, deKernion JB. Spontaneous regression of liver metastasis from renal carcinoma, J. Urol. 140, 596-597 (1988).
51. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol. 148, 1247-1248 (1992).
52. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J. Urol. 154, 28-31 (1995).
53. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159, 1163-1167 (1998).
54. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. Br. J. Urol. Int. 84, 405-411 (1999).
55. Stephenson AJ, Chetner MP, Rourke K et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J. Urol. 172, 58-62 (2004).
56. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J. Urol. 174, 466-472 (2005).
57. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J. Urol. 166, 68-72 (2001).
58. Pantuck AJ, Zisman A, Dorey F et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J. Urol. 169, 2076-2083 (2003).
59. Pantuck AJ, Zisman A, Dorey F et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy Cancer 97, 2995-3002 (2003).
60. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors, J. Urol. 143, 468-473; discussion 473-464 (1990).
61. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J. Urol. 175, 864-869 (2006).
62. Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J. Urol. 157, 2067-2070 (1997).
63. Uzzo RG, Novick AC. Surveillance strategies following surgery for renal cell carcinoma. In: Renal and Adrenal Tumors: Biology and Management. Belldegrun A, Ritchie AWS, Figlin RA, Oliver RTD, Vaughan ED Jr (Eds). Oxford University Press, Oxford, UK 324-330 (2003).
64. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168, 2395-2400 (2002).
65. Shvarts O, Lam JS, Kim HL, Han KR, Figlin R, Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J. Urol. 172, 867-870 (2004).
66. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control, J. Neurosurg. 98, 342-349 (2003).
67. Shuto T, Inomori S, Fujino H, Nagano H. Gamma-knife surgery for metastatic brain tumors from renal cell carcinoma. J. Neurosurg. 105, 555-560 (2006).
68. Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J. Urol. 164, 322-325 (2000).
69. Ramdave S, Thomas GW, Berlangieri SU et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J. Urol. 166, 825-830 (2001).
70. Tollefson MK, Takahashi N, Leibovich BC. Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma. Curr. Urol. Rep. 8, 38-43 (2007).
71. Steinbach F, Novick AC, Zincke H et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J. Urol. 153, 1812-1816 (1995).
72. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J. Urol. 154, 2010-2014; discussion 2014-2015 (1995).
73. Lato JS, Breda A, Belldegrun AS, Figlin RA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J. Clin. Oncol. 24, 5565-5575 (2006).
74. TNM Classification of Malignant Tumours (6th Edition). Sobin LH, Wittekind C (Eds). Wiley-Liss, New York, USA (2002).
75. Frank I, Blute ML, Cheville JC et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J. Urol. 170, 2225-2232 (2003).
76. Ishimura T, Sakai I, Harada K, Hara I, Eto H, Miyake H. Clinicopathological features of recurrence after radical surgery for nonmetastatic renal cell carcinoma. Int. J. Clin. Oncol. 9, 369-372 (2004).
77. Chae EJ, Kim JK, Kim SH, Bae SJ, Cho KS. Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 234, 189-196 (2005).
78. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655-663 (1982).
79. Bani-Hani AH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML. Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients. J. Urol. 173, 391-394 (2005).
80. Sorbellini M, Kattan MW, Snyder ME et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J. Urol. 173, 48-51 (2005).
81. Blute ML, Thibault GP, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Multiple ipsilateral renal tumors discovered at planned nephron sparing surgery: importance of tumor histology and risk of metachronous recurrence. J. Urol. 170, 760-763 (2003).
82. Dimarco DS, Lohse CM, Zincke H, Cheville JC, Blute ML. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy. Urology 64, 462-467 (2004).
83. Lam JS, Shvarts O, Said JW et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 103, 2517-2525 (2005).
84. Klatte T, Chung J, Leppert JT et al. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. Br. J. Urol. Int. 99(4), 821-824 (2007).
85. Van Poppel H, Vandendriessche H, Boel K et al. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. J. Urol. 158, 45-49 (1997).
86. Goncalves PD, Srougi M, Dall'lio MF. Leite KR, Ortiz V, Hering F. Low clinical stage renal cell carcinoma: relevance of microvascular tumor invasion as a prognostic parameter. J. Urol. 172, 470-474 (2004).
87. Kim HL, Belldegrun AS, Freitas DG et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J. Urol. 170, 1742-1746 (2003).
88. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol. 171, 1810-1813 (2004).
89. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 13, 1365-1370 (2006).
90. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66, 1-9 (2005).
91. Di Silverio F, Casale P, Colella D, Andrea L, Seccareccia F, Sciarra A. Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer 88, 835-843 (2000).
92. de Riese WT, Crabtree WN, Allhoff EP et al. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J. Clin. Oncol. 11, 1804-1808 (1993).
93. Lane DP. Cancer. p53, guardian of the genome. Nature 358, 15-16 (1992).
94. Shvarts O, Seligson D, Lam J et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J. Urol. 173, 725-728 (2005).
95. Takamizawa S, Scott D, Wen J et al. The survivin:fas ratio in pediatric renal tumors. J. Pediatr. Surg. 36, 37-42 (2001).
96. Byun SS, Yeo WG, Lee SE, Lee E. Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology 69, 34-37 (2007).
97. Uemura H, Nakagawa Y, Yoshida K et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer 81, 741-746 (1999).
98. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
99. Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol. 171, 2461-2466 (2004).
100. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005).
101. Gilbert SM, Whitson JM, Mansukhani M et al. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology 67, 942-945 (2006).
102. Novick AC, Gephardt G, Guz B, Steinmuller D, Tubbs RR. Long-term follow-up after partial removal of a solitary kidney. N. Engl. J. Med. 325, 1058-1062 (1991).
103. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. N. Am. 30, 843-852 (2003).
104. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal carcinoma. J. Urol. 136, 376-379 (1986).
105. Montie JE. Follow-up after partial or total nephrectomy for renal cell carcinoma. Urol. Clin. N. Am. 21, 589-592 (1994).
106. Gofrit ON, Shapiro A, Kovalski N, Landau EH, Shenfeld OZ, Pode D. Renal cell carcinoma: evaluation of the 1997 TNM system and recommendations for follow-up after surgery. Eur. Urol. 39, 669-674; discussion 675 (2001).
107. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur. Urol. 40, 252-255 (2001).
108. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417 (2000).
109. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166, 63-67 (2001).
110. Hupertan V, Roupret M, Poisson JF et al. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer 107, 2604-2608 (2006).
111. Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97, 1663-1671 (2003).
112. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649-1657 (2001).
113. Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the UCLA integrated staging system for patients with renal cell carcinoma. J. Clin. Oncol. 19, 3792-3793 (2061).
114. Han KR, Bleumer I, Pantuck AJ et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J. Urol. 170, 2221-2224 (2003).
115. Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin. Oncol. 22, 3316-3322 (2004).
116. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20, 4559-4566 (2002).
117. Antonelli A, Cozzoli A, Zani D et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. Br. J. Urol. Int. 99, 296-300 (2007).
118. Cindolo L, de la Taille A, Messina G et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. Br. J Urol. Int. 92, 901-905 (2003).
119. Cindolo L, Patard JJ, Chiodini P et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104, 1362-1371 (2005).
120. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58, 141-145 (2001).
121. Fergany AF, Hafez KS, Novick AC. Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J. Urol. 163, 442-445 (2000).
122. Skolarikos A, Alivizatos G, Laguna P, de la Rosette J. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur. Urol. 51 (6), 1490-1501 (2007).
123. Kaouk JH, Aron M, Rewcastle JC, Gill IS. Cryotherapy: clinical end points and their experimental foundations. Urology 68, 38-44 (2006).
124. Weld KJ, Figenshau RS, Venkatesh R et al. Laparoscopic cryoablation for small renal masses: three-year follow-up. Urology 69, 448-451 (2007).
125. Matin SF, Ahrar K, Cadeddu JA et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J. Urol. 176, 1973-1977 (2006).
126. Lawrentschuk N, Gani J, Riordan R, Esler S, Bolton DM. Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review. Br. J. Urol. Int. 96, 291-295 (2005).
127. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356, 1000-1001 (2000).
128. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch. Dermatol. 139, 928-930 (2003).
129. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch. Dermatol. 139, 903-906 (2003).
130. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: report of a new case with literature review. Am. J. Kidney Dis. 46, 754-759 (2005).
131. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J. Urol. 159, 347-356 (1998).
132. Janzen NK, Laifer-Narin S, Han KR et al. Emerging technologies in uroradiologic imaging. Urol. Oncol. 21, 317-326 (2003).
133. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353, 14-17 (1999).
134. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. CD001425 (2005).
135. Han KR, Pantuck AJ, Bui MH et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology 61, 314-319 (2003)
136. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
137. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
138. Kozlowski JM. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol. Clin. N. Am. 21, 601-624 (1994).
139. O'Dea MJ, Zincke H, Utz DC, Bernatz PE. The treatment of renal cell carcinoma with solitary metastasis. J. Urol. 120, 540-542 (1978).
140. van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FM. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur. Urol. 35, 197-203 (1999).
141. Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur. Urol. 48, 77-81; discussion 81-72 (2005).
142. Tanguay S, Pisters LL, Lawrence DD, Dinney CP. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J. Urol. 155, 26-29 (1996).
143. Friedel G, Pastorino U, Buyse M et al. [Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases - the International Registry of Lung Metastases]. Zentralbl. Chir. 124, 96-103 (1999).
144. Fourquier P, Regnard JF, Rea S, Levi JF, Levasseur P. Lung metastases of renal cell carcinoma: results of surgical resection. Eur. J Candiothorac. Surg. 11, 17-21 (1997).
145. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann. Thorac. Surg. 74, 1653-1657 (2002).
146. Piltz S, Meimarakis G, Wichmann MW, Halz R, Schildberg FW, Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann. Thorac. Surg. 73, 1082-1087 (2002).
147. Jung ST, Ghert MA, Harrelson JM, Scully SP. Treatment of osseous metastases in patients with renal cell carcinoma. Clin. Orthop. Relat. Res. (409), 223-231 (2003).
148. Althausen P, Althausen A, Jennings LC, Mankin HJ. Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80, 1103-1109 (1997).
149. Kollender Y, Bickels J, Price WM et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J. Urol. 164, 1505-1508 (2000).
150. Sundaresan N, Choi IS, Hughes JE, Sachdev VP, Berenstein A. Treatment of spinal metastases from kidney cancer by presurgical embolization and resection. J. Neurosurg. 73, 548-554 (1990).
151. Stief CG, Jahne J, Hagemann JH, Kuczyk M, Jonas U. Surgery for metachronous solitary liver metastases of renal cell carcinoma. J. Urol. 158, 375-377 (1997).
152. Kawata N, Hirakata H, Yuge H et al. Cytoreductive surgery with liver-involved renal cell carcinoma. Int. J. Urol. 7, 382-385 (2000).
153. Alves A, Adam R, Majno P et al. Hepatic resection for metastatic renal tumors: is it worthwhile? Ann. Surg. Oncol. 10, 705-710 (2003).
154. Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 47, 187-193 (1996).
155. Badalament RA, Gluck RW, Wong GY et al. Surgical treatment of brain metastases from renal cell carcinoma. Urology 36, 112-117 (1990).
156. Harada Y, Nonomura N, Kondo M et al. Clinical study of brain metastasis of renal cell carcinoma. Eur. Urol. 36, 230-235 (1999).
157. Schxodter S, Hakenberg OW, Manseck A, Leike S, Wirth MP. Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J. Urol. 167, 1630-1633 (2002).
158. Gogus C, Baltaci S, Beduk Y, Sahinli S, Kupeli S, Gogus O. Isolated local recurrence of renal cell carcinoma after radical nephrectomy: experience with 10 cases. Urology 61, 926-929 (2003).
159. Bruno JJ II, Snyder ME, Motzer RJ, Russo P. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. Br. J. Urol. Int. 97, 933-938 (2006).
160. Frydenberg M, Gunderson L, Hahn G, Fieck J, Zincke H. Preoperative external beam radiotherapy followed by cytoreductive surgery and intraoperative radiotherapy for locally advanced primary or recurrent renal malignancies. J. Urol. 152, 15-21 (1994).
161. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16, 2261-2266 (1998).
162. Esrig D, Ahlering TE, Lieskovsky G, Skinner DG. Experience with fossa recurrence of renal call carcinoma. J. Urol. 147, 1491-1494 (1992).
163. Figlin RA. Renal cell carcinoma: management of advanced disease. J. Urol. 161, 381-386; discussion 386-387 (1999).